PCV14 / Biological E Ltd - LARVOL DELTA

Cost-effectiveness of a 13-valent pneumococcal conjugate vaccine compared with currently available pneumococcal conjugate vaccines in Indian children. (PubMed, IJID Reg) - "This yielded incremental cost-effectiveness ratios (ICERs) for PCV13-PFE vs PCV10-SII and PCV10-GSK of INR 18,142 and INR 304,234 per QALY, respectively, both below the willingness-to-pay threshold of INR 590,949. PCV13-PFE was cost-saving compared to PCV14-BE. From the private sector perspective, vaccinating children in India with PCV13-PFE could prevent more PD cases, save more PD-associated medical costs, and be more cost-effective than other locally available PCV options."

HEOR • Journal • Infectious Disease • Pneumococcal Infections

Cost-Effectiveness of a 13-Valent Pneumococcal Conjugate Vaccine Compared With Currently Available Pneumococcal Conjugate Vaccines in Indian Children (ISPOR-EU 2024) - "From the private sector perspective, vaccinating children with PCV13 could prevent more PD cases, save more PD associated medical costs, and was more cost-effective compared to other alternative vaccination choices."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Pneumococcal Infections

Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study. (PubMed, Vaccine) - "BE-PCV-14 was found to be safe and induced robust and functional serotype specific immune responses to all 14 serotypes. It also elicited cross protective immune response against serotype 6B.These findings suggest that BE-PCV-14 can be safely administered to infants and achieve protection against pneumococcal disease caused by serotypes covered in the vaccine. The study was prospectively registered with clinical trial registry of India - CTRI/2020/02/023129."

Journal • P3 data • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

Presentation Title: Development of a pneumococcal conjugate vaccine and novel vaccines through research driven efforts in India (VACCINES SUMMIT 2023) - "A fourteen valent conjugate vaccine (PCV14) (Serotypes 1,3,4,5,6B,7V ,9F,14,18C,19A,19F,22F,23F, and 33F) was developed and Preclinical animal safety studies were done and the vaccine was tested in Phase1 clinical study adults for safety...This 9-year long journey was a good learning experience on how to overcome limitations to develop complex vaccines in a developing world like India. A next gen PCV24 development was also initiated."

Infectious Disease • Pneumococcal Infections